|
|
Blood, 4 June 2009, Vol. 113, No. 23, pp. 5737-5742.
Prepublished online as a Blood First Edition Paper on March 31, 2009; DOI 10.1182/blood-2009-02-204172.
 Previous Article | Next Article 
Submitted February 9, 2009
Accepted March 18, 2009
Hodgkin lymphoma in the Swiss HIV Cohort Study
Gary M. Clifford*, Martin Rickenbach, Mauro Lise, Luigino Dal Maso, Manuel Battegay, Julia Bohlius, Emmanuelle Boffi El Amari, Urs Karrer, Gernot Jundt, Andrea Bordoni, Silvia Ess, and Silvia Franceschi
International Agency for Research on Cancer, Lyon, France
Coordination and Data Center, Swiss HIV Cohort Study, Lausanne, Switzerland
Epidemiology and Biostatistics Unit, Aviano Cancer Center, Aviano, Italy
Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Geneva University Hospital, Geneva, Switzerland
Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, Switzerland
Cancer Registry of Basel, Basel, Switzerland
Cancer Registry of the Canton of Ticino, Locarno, Switzerland
Cancer Registry of St Gallen and Appenzell, St Gallen, Switzerland
* Corresponding author; email: clifford{at}iarc.fr.
Hodgkin lymphoma (HL) risk is elevated among persons infected with HIV (PHIV) and has been suggested to have increased in the era of combined antiretroviral therapy (cART). Among 14,606 PHIV followed over 20 years in the Swiss HIV Cohort Study (SHCS), determinants of HL were investigated using two different approaches, namely a cohort and nested case-control study, estimating hazard ratios (HR) and matched odds ratios (OR) respectively. Forty-seven incident HL cases occurred during 84,611 person-years of SHCS follow-up. HL risk was significantly higher among men having sex with men (HR versus intravenous drug users=2.44, 95% confidence interval [CI]: 1.13-5.24) but did not vary by calendar period (HR for 2002-2007 versus  1995=0.65, 95% CI: 0.29-1.44) nor cART use (HR versus non-users=1.02, 95% CI: 0.53-1.94). HL risk tended to increase with declining CD4+ cell counts, but these differences were not significant. A lower CD4+/CD8+ ratio at SHCS enrolment or 1-2 years prior to HL, however, was significantly associated with increased HL risk. In conclusion, HL risk does not appear to be increasing in recent years or among PHIV using cART in Switzerland, and there was no evidence that HL risk should be increased in the setting of improved immunity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter
- Riccardo Dolcetti, Paolo De Paoli, and Diego Serraino
Blood 2009 114: 2354.
[Full Text]
[PDF]
-
Response: Lymphocyte counts prior to Hodgkin lymphoma development
- Gary Clifford, Silvia Franceschi, and Martin Rickenbach
Blood 2009 114: 2354-2355.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Dolcetti, P. De Paoli, and D. Serraino
Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter
Blood,
September 10, 2009;
114(11):
2354 - 2354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Clifford, S. Franceschi, and M. Rickenbach
Response: Lymphocyte counts prior to Hodgkin lymphoma development
Blood,
September 10, 2009;
114(11):
2354 - 2355.
[Full Text]
[PDF]
|
|
|
|
|
